AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-8. (Canceled)

Claim 9. (Currently Amended) A method for treating a disease and/or condition associated with the excessive release of glutamate in a patient comprising administration to said patient of a composition containing a therapeutically effective amount of at least one beta-naphthoquinone derivative and a pharmaceutically acceptable carrier, wherein said beta-naphthoquinone derivative is selected among the group consisting of:

(i)   compounds having the formula (I):

(I)

wherein R represents -NH-CO-NH2, -NH-CO-CH3, or -OH group,

(ii)   glucuronide derivatives thereof having the formula (II):

OH
OH
HO
O O
COOH
N — R
(II)

wherein R is as indicated in (i), and

(iii) addition salts thereof.

Claim 10. (Previously Presented). The method of claim 9, wherein said beta-naphthoguinone derivative is selected among the group consisting of the 1,2-naphthoquinone, 2-semicarbazone and the 1-(1-hydroxy,2-naphthyl)semicarbazide-1-β-O-gluco-pyranosiduronic acid.

Claim 11. (Currently Amended) The method of claim 10, wherein said disease and/or condition associated with the excessive release of glutamate is selected among from the group consisting of epileptic seizures, acute neurodegenerative diseases, and chronic neurodegenerative diseases, ischemia, Alzheimer's, Huntington's, Parkinson's diseases, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), retinopathy, stroke and traumatic brain injury, drug-induced neurotoxicity, pain, hormonal balance disorders, blood pressure disorders, thermoregulation disorders, respiration disorders, learning disorders, pattern recognition disorders, memory disorders, and disorders subsequent to hypoxia or hypoglycaemia.

Claim 12. (New) The method of claim 11, wherein said acute or chronic neurodegenerative diseases are selected from the group consisting of Alzheimer's disease, Huntington's disease, Parkinson's disease, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), retinopathy, stroke, and traumatic brain injury.